Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SEATTLE, Dec. 27, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Adaptive Biotechnologies’ management is scheduled to present on Monday, January 9th at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Mary Pat Lancelotta
206-600-6702
media@adaptivebiotech.com

Staff

Recent Posts

Skypoint Launches Lia and Scribe: AI-Powered Agents Redefining Clinical Workflow Efficiency and Social Determinants of Health (SDOH) Data Capture

PORTLAND, Ore., June 13, 2025 /PRNewswire/ -- Skypoint, a leading provider of HITRUST r2-certified AI platform…

2 hours ago

Prior to FIFA Club World Cup Kickoff, FC Mother and Omya Launch Landmark Joint Venture to Fund “Life Years” as Part of World Cup of Healing Legacy Project

First-of-its-kind joint venture funds longevity gains and maternal healing through football, creating a new category…

2 hours ago

Personal Safety Tracking Devices Market to Reach USD 1.6 Billion by 2030, Driven by GPS and Bluetooth Advancements | Valuates Reports

BANGALORE, India, June 13, 2025 /PRNewswire/ -- Personal Safety Tracking Devices Market is Segmented by Type…

2 hours ago

Dana Foundation Recognizes Two Neuroscience & Society Champions with Inaugural Awards

Neuroethicist and psychiatrist are recognized for innovation and transformative interdisciplinary work to advance neuroscience's benefits…

2 hours ago

Clear Guide Medical LUMENA™ Featured in SPIE Study on MRI-Guided Interventions

BALTIMORE, June 13, 2025 /PRNewswire/ -- Clear Guide Medical, a leader in AI- and AR-powered…

2 hours ago